K. Peter Hirth

SU5416 is a potent and selective inhibitor of the vascular endothelial growth factor receptor (Flk-1/KDR) that inhibits tyrosine kinase catalysis, tumor vascularization, and growth of multiple tumor types.

T. Annie T. Fong, Laura K. Shawver, Li Sun et al. · PubMed · 1999 · 1K citations

Novel Synthetic Compound, Chemoprevention Strategy, Pathology +20

Inhibition of angiogenesis decreases alveolarization in the developing rat lung

Malathi Jakkula, Timothy D. Le Cras, Sarah A. Gebb et al. · American Journal of Physiology-Lung Cellular and Molecular Physiology · 2000 · 663 citations

Inflammatory Lung Disease, Lung Inflammation, Immunology +20

SU6668 is a potent antiangiogenic and antitumor agent that induces regression of established tumors.

Alexander Laird, Peter Vajkoczy, Laura K. Shawver et al. · PubMed · 2000 · 497 citations

Pathology, Cancer Biology, Tumor Biology +23

Scaffold-based discovery of indeglitazar, a PPAR pan-active anti-diabetic agent

Dean R. Artis, Jack J. Lin, Chao Zhang et al. · Proceedings of the National Academy of Sciences · 2008 · 146 citations · Full text

Metabolic Syndrome, Medicinal Chemistry, Biochemistry +15

Inhibition of Tumor Growth, Angiogenesis, and Microcirculation by the Novel Flk-1 Inhibitor SU5416 as Assessed by Intravital Multi-fluorescence Videomicroscopy

Peter Vajkoczy, Michael D. Menger, Brigitte Vollmar et al. · Neoplasia · 1999 · 144 citations · Full text

Biomedical Engineering, Glioma, Angiogenesis Blockage +17